Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era
BackgroundSince the first data of the BILCAP trial was presented in 2017, capecitabine became standard adjuvant treatment for intrahepatic cholangiocarcinoma (ICC). For ICC, the efficacy of capecitabine on survival outcomes remains unresolved as the BILCAP trial included all entities of biliary trac...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2026-06-01
|
| Seri Bilgileri: | Frontiers in Surgery |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fsurg.2026.1853219/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|